Study on the efficacy and safety of dorzagliatin combined with metformin in the treatment of type 2 diabetes mellitus patients with initially overweight/obesity
10.3969/j.issn.1673-9701.2024.34.014
- VernacularTitle:多格列艾汀联合二甲双胍治疗初发超重/肥胖2型糖尿病患者的有效性及安全性研究
- Author:
Wanwan PENG
1
;
Junli XUE
1
;
Jiao'e ZENG
1
Author Information
1. 荆州市中心医院内分泌科,湖北荆州 434020
- Publication Type:Journal Article
- Keywords:
Dorzagliatin;
Metformin;
Overweight;
Obesity;
Type 2 diabetic mellitus
- From:
China Modern Doctor
2024;62(34):63-67
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the safety and efficacy of dorzagliatin combined with metformin in the treatment of type 2 diabetes mellitus (T2DM) patients with initially overweight/obesity. Methods Eighty T2DM patients with initially overweight/obesity diagnosed in the Department of Endocrinology of Jingzhou Central Hospital from October 2023 to April 2024 were selected. They were divided into control group and observation group with 40 cases in each group by random number table method. Control group was treated with metformin,observation group was treated with dorzagliatin combined with metformin. After 12 weeks of treatment,the therapeutic effects,and fasting blood glucose (FBG),2-h postprandial blood glucose (2hPG),glycosylated hemoglobin (HbA1c),homeostasis model assessment for β cell function (HOMA-β),homeostasis model assessment of insulin resistance (HOMA-IR) index,quality of life scale for patients with type 2 diabetes mellitus (DMQLS) scores,estimated glomerular filtration rate,liver function and lipid level before and after treatment were compared between two groups. The occurrence of adverse reactions during medication was recorded. Results The total effective rate of observation group was significantly higher than that of control group (95.00％ vs. 77.50％,x2=5.165,P=0.023). After treatment,FBG,2hPG,HbA1c,HOMA-IR index and body mass index of patients in both groups were significantly lower than before treatment,while HOMA-β and DMQLS scores were significantly higher than before treatment (P<0.05). FBG,2hPG,HbA1c,HOMA-IR index and body mass index of patients in observation group were significantly lower than those in control group,while HOMA-β and DMQLS scores were significantly higher than those in control group (P<0.05). There were no serious adverse reactions occurred during treatment in two groups (P>0.05). Conclusion The effect of dorzagliatin combined with metformin in the treatment of T2DM patients with initially overweight/obesity is remarkable. It can effectively control the level of blood glucose,improve the function of pancreatic islet cells,lose weight,and improve the life quality of patients. Its clinical application value is outstanding.
